Research Topics
Species | H OettleSummaryAffiliation: Humboldt University Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)Hanno Riess
Charite Campus Virchow Clinic, Medical Clinic Hematology Oncology, Augustenburger Platz 1, 13353 Berlin, Germany
BMC Cancer 8:361. 2008..This phase IIb study was designed to analyze the efficacy of enoxaparin in patients with locally advanced or metastatic pancreatic cancer undergoing systemic chemotherapy...- A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancerHelmut Friess
Department of General Surgery, University of Heidelberg, Heidelberg, Germany
BMC Cancer 6:285. 2006..In this study, the treatment effects of the angiogenesis inhibitor Cilengitide and gemcitabine were compared with gemcitabine alone in patients with advanced unresectable pancreatic cancer... - Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II studyUwe Pelzer
Universitatsmedizin Berlin, Charité Centrum für Tumormedizin, CONKO Study Group, Augustenburger Platz 1, Berlin, Germany
BMC Cancer 10:86. 2010..The positive influence of BIA determinate predictors by additional nutrition is currently under discussion... 
Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancerH Oettle
Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Charite, Campus Virchow Klinikum, Medizinische Facultät der Humboldt Universität zu Berlin, Germany
Anticancer Drugs 13:833-8. 2002....- Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trialHelmut Oettle
Department of Medical Oncology and Hematology, Charite School of Medicine, Campus Virchow Klinikum, Berlin, Germany
JAMA 297:267-77. 2007..The role of adjuvant therapy in resectable pancreatic cancer is still uncertain, and no recommended standard exists... - Recombinant human erythropoietin in the treatment of head and neck tumour anaemiaH Oettle
Charite Campus Virchow Klinikum, Medical Faculty of the Humboldt University in Berlin Germany
Int J Oral Maxillofac Surg 30:148-55. 2001..Recombinant human erythropoietin administration improves the therapeutic outcome and the patients' prognosis... - Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancerH Oettle
Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
Anticancer Drugs 10:699-704. 1999..The median time to progressive disease was 31 weeks (range 5-50 weeks). A phase 11 trial is underway to further assess the activity of this combination at the recommended dose of 750 mg/m2 5-FU... - The role of gemcitabine alone and in combination in the treatment of pancreatic cancerH Oettle
Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
Anticancer Drugs 11:771-86. 2000..The data suggest that gemcitabine in combination with biomodulated 5-FU should be considered the standard palliative treatment to which other new drug combinations or combined modality chemoradiation regimens should be compared... - Adjuvant therapy in pancreatic cancer: a critical appraisalHelmut Oettle
Department of Medical Hematology and Oncology, Charité Berlin University School of Medicine, Campus Virchow Klinikum, Berlin, Germany
Drugs 67:2293-310. 2007.... - Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinomaH Oettle
Charite Campus Virchow Klinikum, Medizinische Fakultat der Humboldt Universitat zu Berlin, Medizinische Klinik und Poliklinik mS Hämatologie und Onkologie, Berlin, Germany
Anticancer Drugs 11:635-8. 2000..This opens up an additional therapeutic option for a selected patient group with a poor prognosis so far... - Elevated reticulocyte count--a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case reportS Serke
Department of Haematology Oncology, Charite, Campus Virchow Klinikum, , Berlin, Germany
Br J Cancer 79:1519-21. 1999..Re-exposure to gemcitabine 6 months after the episode of HUS instituted for progressive carcinoma, thus far has not caused another episode of HUS... - [Adjuvant treatment of pancreatic cancer]H Oettle
Charite Campus Virchow Klinikum, Medizinische Fakultat der Humboldt Universitat zu Berlin, Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie
Zentralbl Chir 128:411-8. 2003..These studies have also included arms with gemcitabine, the current standard for palliative treatment of pancreatic cancer, and will hopefully allow firm conclusions as to the role of postoperative chemotherapy... - Interferon-induced remission of rapidly growing aggressive fibromatosis in the temporal fossaJ D Raguse
Klinik und Poliklinik fur Mund, Kiefer und Gesichtschirurgie, Plastische Operationen, Germany
Int J Oral Maxillofac Surg 33:606-9. 2004..The patient received interferon alpha2a subcutaneously for 6 months. A slow but steady reduction of the tumour was observed, and pre-existing symptoms disappeared... - Gemcitabine in the treatment of advanced head and neck cancerJ D Raguse
Clinic and Policlinic for Oral and Maxillofacial Surgery, Plastic Surgery, Germany
Clin Oncol (R Coll Radiol) 17:425-9. 2005..Gemcitabine has demonstrated a broad spectrum anti-tumoural effect and a favourable toxicity profile. These attributes prompted us to introduce gemcitabine into the treatment of head-and-neck tumours... - [Potential advantages of the MRI for the radiofrequency ablation of liver tumors]G Gaffke
Klinik für Strahlenheilkunde und Poliklinik, Charite, Universitatsmedizin Berlin
Rofo 177:77-83. 2005..To present first results of radiofrequency ablation of liver tumors using a new MR compatible applicator... - [Adjuvant therapy of pancreatic carcinoma]H Oettle
Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin
Praxis (Bern 1994) 89:2017-25. 2000..In a multicenter German trial the benefit of gemcitabene as weekly monotherapy for 6 months is investigated. The treatment starts soon after resection due to low toxicity and good patient compliance... - A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancerH Oettle
Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
Ann Oncol 11:1267-72. 2000..The present study was initiated to investigate the efficacy of gemcitabine in combination with 5-FU-FA... - [Current concepts and recent developments of laser ablation in tumor therapy]C Stroszczynski
Klinik für Strahlenheilkunde der Charité, Campus Virchow Klinikum und Campus Buch Medizinische Fakultät der Humboldt Universität zu Berlin
Radiologe 44:320-9. 2004..The procedure was done using a combination of imaging modalities (CT/MRI, CT/US) or only closed high field MRI (1.5 T). All patients received an MRI-scan immediately after laser ablation... - Oxaliplatin, folinic acid and 5-fluorouracil (OFF) in patients with recurrent advanced head and neck cancer: a phase II feasibility studyJan Dirk Raguse
Clinic and Policlinic for Oral and Maxillofacial Surgery, Plastic Surgery, Clinical Navigation and Robotics, Charite Universitatsmedizin Berlin, Campus Virchow Hospital, Augustenburger Platz 1, 13353 Berlin, Germany
Oral Oncol 42:614-8. 2006..In this small phase II study the combination of oxaliplatin, FA and 5-FU (OFF) demonstrated relative to the standard regimen of cisplatin and 5-FU a high antitumoural activity in previously treated scchn with favourable toxicity profile... 
Gemcitabine in the treatment of metastatic pancreatic cancerAndreas Hilbig
Department of Medical Hematology and Oncology, Charite School of Medicine, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
Expert Rev Anticancer Ther 8:511-23. 2008..The emerging role of combinations of gemcitabine with novel targeted agents, including small-molecule inhibitors and other investigational drugs, is also discussed...- Second-line therapy in refractory pancreatic cancer. results of a phase II studyUwe Pelzer
Universitatsmedizin Berlin, CharitéCentrum fur Tumormedizin, Medizinische Klinik m S Hamatologie Onkologie, Berlin, Germany
Onkologie 32:99-102. 2009.... - Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9Jan Däbritz
Department of Medical Oncology and Hematology, Charite School of Medicine, Campus Virchow Klinikum, Humboldt University of Berlin, Berlin, Germany
Pancreas 38:534-41. 2009..We followed up the presence of Kirsten rat sarcoma (K-ras) mutations in plasma DNA and assessed its clinical value in patients with pancreatic cancer... - Changing impact of cytomegalovirus in liver transplantation -- a single centre experience of more than 1000 transplantations without ganciclovir prophylaxisDaniel Seehofer
Department of General, Visceral and Transplant Surgery, Humboldt University of Berlin, Berlin, Germany
Transpl Int 18:941-8. 2005..As D+R- patients still more often develop symptomatic disease, pre-emptive therapy could be useful in this patient group... - Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRIJuri Ruf
Klinik fur Strahlenheilkunde und PET Zentrum Berlin, Berlin, Germany
Pancreatology 5:266-72. 2005..To determine the value of fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for the detection of recurrent pancreatic cancer in comparison to computed tomography (CT) and magnetic resonance imaging (MRI)... - Adjuvant therapy of pancreatic cancerAndreas Hilbig
Campus Virchow Klinikum, Medizinische Klinik M S Hämatologie und Onkologie Augustenburger Platz 1, 13353 Berlin, Germany
Expert Rev Anticancer Ther 10:485-91. 2010..Early data from the European Study Group for Pancreatic Cancer-3(v2) trial revealed no difference in terms of overall survival between 5-fluorouracil/folinic acid and gemcitabine after resection of pancreatic cancer... - Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancerHelmut Oettle
Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Medizinische Fakultat der Humboldt Universitat zu Berlin, Berlin, Germany
Cancer 95:912-22. 2002..However, the results of ongoing Phase III studies must be reviewed before a definitive statement can be made regarding the value of this combination in the treatment of pancreatic cancer... - Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumourJan Dirk Raguse
Klinik fur Mund, Kiefer und Gesichtschirurgie, klinische Navigation und Robotik Plastische Operationen, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Augustenburgerplatz 1, 13353 Berlin, Germany
Oral Oncol 40:228-30. 2004..case demonstrates the clinical efficacy of the antiangiogenetic agent cilengitide, in combination with gemcitabine, in inhibiting rapid growth of highly vascularized tumour and highlights the potential of this new therapeutic agent.. - Quantitation of cytomegalovirus (hCMV) DNA and beta-actin DNA by duplex real-time fluorescence PCR in solid organ (liver) transplant recipientsJoachim Hänfler
Department of Medicine, Division of Hematology and Oncology, Charite Campus Virchow Klinikum, Humboldt University Berlin, Augustenburger Platz 1, 13353, Berlin, Germany
Med Microbiol Immunol 192:197-204. 2003..We conclude that with the presented method the reliability of hCMV quantitation via real-time PCR can be substantially increased and may be used to monitor hCMV kinetics in vivo... - A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancerH Oettle
University of Berlin, Berlin, Germany
Ann Oncol 16:1639-45. 2005..This randomized phase III study compared the overall survival (OS) of pemetrexed plus gemcitabine (PG) versus standard gemcitabine (G) in patients with advanced pancreatic cancer... - Histopathological correlation to MRI findings during and after laser-induced thermotherapy in a pig pancreas modelC Stroszczynski
Radiology Charité Campus Buch, Robert Roessle Klinik am Max Delbrueck Center of Molecular Medicine, Berlin, Germany
Invest Radiol 36:413-21. 2001..To investigate whether percutaneous laser-induced thermotherapy (LITT) with continuous magnetic resonance (MR) monitoring of thermal effects within the pancreas is feasible in a porcine model... - Pancreatic cancer: step by step forwardH Riess
, Campus Virchow-Klinikum, , Berlin, Germany
Recent Results Cancer Res 177:1-2. 2008 - Mutational analysis of K-ras codon 12 in blood samples of patients with acute myeloid leukemiaRoman Preston
Department of Medical Oncology and Hematology, Charite School of Medicine, Campus Virchow Klinikum, Berlin, Germany
Leuk Res 34:883-91. 2010..Correlation with clinical data suggests K-ras mutations to be associated with higher age and a better response to anti-leukemic chemotherapy... - Role of F18-FDG PET for monitoring of radiochemotherapy -- estimation of detectable number of tumour cellsJ Ruf
, Charit, , Campus Virchow-Klinikum, Berlin, Germany
Onkologie 27:287-90. 2004..CONCLUSION: The number of vital tumour cells within this specimen was estimated to be 10(6)-10(7). The detection threshold for FDG-PET in pancreatic carcinoma appears to be within this range... - Use of semiflexible applicators for radiofrequency ablation of liver tumorsG Gaffke
Klinik für Strahlenheilkunde und Poliklinik, Charite, Universitatsmedizin Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany
Cardiovasc Intervent Radiol 29:270-5. 2006..To evaluate the feasibility and potential advantages of the radiofrequency ablation of liver tumors using new MRI-compatible semiflexible applicators in a closed-bore high-field MRI scanner... - Presence of human beta- and gamma-herpes virus DNA in Hodgkin's diseaseC A Schmidt
Abteilung fur Innere Medizin, Hämatologie und Onkologie, Virchow Klinikum, Humboldt Universitat, Berlin, Germany
Leuk Res 24:865-70. 2000..In contrast to EBV, beta-herpes viruses are therefore unlikely to have a role in the aetiology of HD. Rather, the presence of these viruses seems to reflect impaired immunological surveillance... - Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probesJ Däbritz
Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Augustenburger Platz 1, 13353 Berlin, Germany
Br J Cancer 92:405-12. 2005..In addition, this method can be adapted for simultanous detection of multiple mutations and quantitation... - The role of epoxide hydrolase Y113H gene variant in pancreatic diseasesJohann Ockenga
Department of Gastroenterology, Hepatology and Endocrinology, Charite, Campus Mitte, Germany
Pancreas 38:e97-e101. 2009..We studied the role of the EPHX1 c.337T>C (p.Y113H) variant, whichleads to altered enzyme activity, in pancreatic diseases... - Quantitation of the spliced late gene of human cytomegalovirus and its kinetics during experimental infectionJoachim Hänfler
Department of Medicine, Humboldt University Berlin, Germany
Med Microbiol Immunol 190:161-5. 2002.... - Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization scheduleLars Meyer
J Clin Oncol 20:1146-7. 2002 - Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)Hermann Einsele
Dept of Hematology, Oncology, Medical Clinic II, University of Tubingen, Otfried Muller Strasse 10, 72076, Tubingen, Germany
Ann Hematol 82:S175-85. 2003..Infection-associated mortality, for example, is significantly higher following engraftment than during the short neutropenic period that immediately follows transplantation...